27
Participants
Start Date
November 30, 2025
Primary Completion Date
December 31, 2028
Study Completion Date
December 31, 2043
i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells
Dose Level 1: 3 x 10\^8/m\^2 of i15.NKG2D.zeta NK cells and 3 x 10\^7/m\^2 of C7R.GD2.CAR T cells given 5 days later.
i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells
Dose Level 2: 6 x 10\^8/m\^2 of i15.NKG2D.zeta NK cells and 3 x 10\^7 cells/m\^2 of C7R.GD2.CAR T cells given 5 days later.
i15.NKG2D.zeta NK cells and C7R.GD2.CARTs cells
Dose Level 3: 12 x 10\^8/m\^2 of i15.NKG2D.zeta NK cells and 3 x 10\^7 cells/m\^2 of C7R.GD2.CAR T cells given 5 days later.
Texas Children's Hospital, Houston
Center for Cell and Gene Therapy, Baylor College of Medicine
OTHER
Baylor College of Medicine
OTHER